184
Results-
Press ReleasePierre Fabre consolidates its unique expertise in dermatology by creating the largest international databaseCreated on : - Last modified on :The ALL project : more than 50,000 people surveyed in 20 countries on 5 continents Castres, June 20 , 2023 - On the occasion of the 25th World Congress of Dermatology (WCD), which will be held in Singapore from July 4 to 7, the Pierre Fabre Patient Relations Department will present the ALL project, a large-scale survey, the largest ever conducted in dermatology.
-
Press ReleasePierre Fabre announces the acquisition of MÊMECreated on : - Last modified on :MÊME, the first dermo-cosmetic brand for patients experiencing the side effects of cancer treatments
-
Press ReleaseTalem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre FabreCreated on : - Last modified on :
-
Press ReleaseHervé Hoppenot, Incyte CEO, is appointed on the Board of Pierre Fabre LaboratoriesCreated on : - Last modified on :Castres (France), January 5th, 2024 – President and CEO of the biotechnology company Incyte since 2014, Hervé Hoppenot will bring his extensive pharmaceutical expertise to the Board of Directors of Pierre Fabre Laboratories, particularly in the field of oncology. His appointment comes at a time when Pierre Fabre is preparing to market in the US its allogeneic immunotherapy Ebvallo® which has just been awarded the prestigious Prix Galien for its therapeutic innovation.
-
Press ReleasePierre Fabre Invest acquires a majority stake in the share capital of Ladrôme, a company specializing in organic natural health productsCreated on : - Last modified on :Castres (Tarn) and Saillans (Drôme), November 22, 2021 - Pierre Fabre Invest, a Pierre Fabre Group subsidiary dedicated to investments, has announced the acquisition of a majority stake in the share capital of Ladrôme. Founded in 1999, Ladrôme is specialized in the development, manufacturing and marketing of aromatherapy and phytotherapy products formulated exclusively from organically grown plants in accordance with the highest standards and certifications in the industry.
-
Press ReleasePIERRE FABRE LABORATORIES ACQUIRES A STAKE IN MIYÉCreated on : - Last modified on :PIERRE FABRE LABORATORIES INVESTS IN MIYÉ, A START-UP SPECIALIZING IN HORMONAL BALANCE AND WELL-BEING
-
Press ReleaseEau Thermale Avène hits a billion euros in turnover, and strengthens its medical positioning.Created on : - Last modified on :Toulouse, January 23, 2024 - Eau Thermale Avène, committed to advancing dermatology and improving the management of all skin conditions since 1990, becomes the first Pierre Fabre Laboratories brand to reach one billion euros in turnover. Supported by an international network of 80,000 prescribers, 130 million units of Avène products were sold in 2023. The brand's momentum is on display both in France, where the brand is leader in the pharmacy channel*, and in the 115 international markets that accounted for 77% of its revenues in 2023.
-
Press ReleasePierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies.Created on : - Last modified on :70% of rare genetic diseases start in childhood (1,2).
-
Press ReleasePierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.Created on : - Last modified on :Castres (France), Geneva (Switzerland), 15 February 2024 – On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be held in Brussels.
-
Press ReleaseKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesCreated on : - Last modified on :• Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.• The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.